Reference SummaryTurusov VS, Int J Cancer 1992 Jan 2;50(1):131-5

Title

Occurrence of tumours in the descendants of CBA male mice prenatally treated with diethylstilbestrol.

Authors

Turusov VS; Trukhanova LS; Parfenov YuD; Tomatis L

Journal

Int J Cancer

Volume

50

Issue

1

Year

1992

Pages

131-5

Abstract

There is well documented evidence both in humans and in experimental animals that exposure to diethylstilbestrol (DES) during pregnancy results in an increased incidence of tumours in the progeny. The increased cancer risk has been reported to persist in the second generation descendants of DES-exposed pregnant mice. In the present experiment, female mice of the CBA strain were treated at day 17 of pregnancy with 1 microgram/g body weight of DES. The descendants of DES-treated mothers, described as F1DES, were mated among each other or with untreated animals. The F1DES females were found to be sterile when mated with either F1DES or untreated males. F1DES males were successfully mated with untreated females. In the female offspring so obtained, but not in the male, a statistically significant increased incidence of tumours was observed, in particular of uterine sarcomas, and also of benign ovarian tumours and of lymphomas.

Links

J:2844 – Mouse Genome Informatics
1728603 – National Library of Medicine/PubMed

Models

Strain Model Name Treatment Agent(s) Organ Affected Frequency Model Details
CBA Adrenal gland - Cortex adenoma
  • diethylstilbestrol (DES)
Adrenal gland - Cortex

1.2

CBA Kidney adenoma
  • diethylstilbestrol (DES)
Kidney

2.5

CBA Kidney adenoma Kidney

1.9 - 2.4

CBA Kidney carcinoma
  • diethylstilbestrol (DES)
Kidney

1.0

CBA Leukocyte - Monocyte - Macrophage - Histiocyte histiocytic sarcoma
  • diethylstilbestrol (DES)
Uterus

10.9 - 16.7

CBA Leukocyte - Monocyte - Macrophage - Histiocyte histiocytic sarcoma Uterus

4.9 - 6.0

CBA Leukocyte - Monocyte - Macrophage - Histiocyte histiocytoma - malignant
  • diethylstilbestrol (DES)
Skin

1.2 - 2.5

CBA Leukocyte lymphoma
  • diethylstilbestrol (DES)
Leukocyte

2.2 - 20.2

CBA Leukocyte lymphoma Leukocyte

0 - 12.2

CBA Liver tumor
  • diethylstilbestrol (DES)
Liver

0 - 46.1

CBA Liver tumor Liver

5.0 - 51.9

CBA Lung tumor
  • diethylstilbestrol (DES)
Lung

2.2 - 20.0

CBA Lung tumor Lung

5.0 - 25.6

CBA Mammary gland carcinoma
  • diethylstilbestrol (DES)
Mammary gland

0 - 50

CBA Mammary gland carcinoma Mammary gland

0 - 13.4

CBA Mesodermal cell/mesoblast sarcoma
  • diethylstilbestrol (DES)
Uterus

10.9 - 25

CBA Mesodermal cell/mesoblast sarcoma
  • diethylstilbestrol (DES)
Mesodermal cell/mesoblast

2.5

CBA Mesodermal cell/mesoblast sarcoma Uterus

0 - 6.0

CBA Mesodermal cell/mesoblast sarcoma Mesodermal cell/mesoblast

1.9 - 4.9

CBA Ovary - Granulosa cell tumor - malignant
  • diethylstilbestrol (DES)
Ovary - Granulosa cell

1.2

CBA Ovary adenoma - tubular
  • diethylstilbestrol (DES)
Ovary

observed

CBA Ovary adenoma - tubular Ovary

observed

CBA Ovary tumor
  • diethylstilbestrol (DES)
Ovary

0 - 19.0

CBA Ovary tumor Ovary

5.0 - 9.0

CBA Ovary tumor - granulosa-theca cell - benign
  • diethylstilbestrol (DES)
Ovary

observed

CBA Ovary tumor - granulosa-theca cell - benign Ovary

observed

CBA Seminal vesicle adenoma
  • diethylstilbestrol (DES)
Seminal vesicle

2.5

CBA Skin carcinoma
  • diethylstilbestrol (DES)
Skin

1.2

CBA Testis tumor - malignant
  • diethylstilbestrol (DES)
Testis

1.0

CBA Uterus adenocarcinoma
  • diethylstilbestrol (DES)
Uterus

2.4

CBA Uterus carcinoma
  • diethylstilbestrol (DES)
Uterus

0 - 2.4

CBA Uterus carcinoma Uterus

0

CBA Uterus polyp - fibrous
  • diethylstilbestrol (DES)
Uterus

6.25

CBA (Unspecified organ) angiosarcoma
  • diethylstilbestrol (DES)
Vagina

1.2

CBA (Unspecified organ) angiosarcoma
  • diethylstilbestrol (DES)
Prostate gland

1.0

CBA (Unspecified organ) tumor
  • diethylstilbestrol (DES)
(Unspecified organ)

2.2 - 12.5

CBA (Unspecified organ) tumor (Unspecified organ)

8.5 - 23.1